Clinuvel Pharmaceuticals Ltd. plans to complete a European regulatory filing for its lead drug Scenesse (afamelanotide) in the coming weeks, following a Phase III clinical trial in patients with erythropoietic protoporphyria (EPP), which met its primary endpoint.